Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) tumbled 5.46% in after-hours trading on Tuesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's performance fell short of market expectations in key areas, prompting a negative reaction from investors.
Pacira reported total revenues of $181.1 million for the quarter, missing the analyst consensus estimate of $183 million. This represents a marginal increase of 1.73% compared to the same period last year. Despite the revenue miss, the company's adjusted earnings per share (EPS) of $0.74 beat the estimated $0.71, showcasing some resilience in its bottom line.
However, investors seemed more concerned about Pacira's net loss of $4.8 million for the quarter and its decision to narrow its full-year 2025 revenue guidance. The company now expects total revenue between $730 million and $750 million, down from the previous range of $725 million to $765 million. This adjustment, coupled with the Q2 performance, appears to have dampened market sentiment, leading to the significant after-hours decline in stock price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。